



of the Main Protease
Luca Pinzi 1, Annachiara Tinivella1,2, Fabiana Caporuscio1 and Giulio Rastelli 1*
1Molecular Modelling and Drug Design Lab, Life Sciences Department, University of Modena and Reggio Emilia, Modena, Italy,
2Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy
The outbreak of a new coronavirus (SARS-CoV-2), which is responsible for the COVID-19
disease and is spreading rapidly around the world, urgently requires effective therapeutic
treatments. In this context, drug repurposing represents a valuable strategy, as it enables
accelerating the identification of drug candidates with already known safety profiles, possibly
aiding in the late stages of clinical evaluation. Moreover, therapeutic treatments based on drugs
with beneficial multi-target activities (polypharmacology)may show an increased antiviral activity
or help to counteract severe complications concurrently affecting COVID-19 patients. In this
study, we present the results of a computational drug repurposing campaign that aimed at
identifying potential inhibitors of the main protease (Mpro) of the SARS-CoV-2. The performed in
silico screening allowed the identification of 22 candidates with putative SARS-CoV-2 Mpro
inhibitory activity. Interestingly, some of the identified compounds have recently entered clinical
trials for COVID-19 treatment, albeit not being assayed for their SARS-CoV-2 antiviral activity.
Some candidates present a polypharmacology profile that may be beneficial for COVID-19
treatment and, to the best of our knowledge, have never been considered in clinical trials. For
each repurposed compound, its therapeutic relevance and potential beneficial
polypharmacological effects that may arise due to its original therapeutic indication are
thoroughly discussed.
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INTRODUCTION
At present, we are faced with one of the most devastating pandemic crises in human history, the
coronavirus disease 2019 (COVID-19), which has affected around 56 million people to date and
is responsible for more than 1.38 million deaths (Who.int1). Unfortunately, effective therapeutic
options are not currently available to prevent or cure this disease, which is caused by the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Who.int1). Only very recently, Pfizer,
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(Comirnaty) to Food and Drug Administration (FDA), for an
Emergency Use Authorization (EUA) (Pfizer Inc.2) and
received a Conditional Marketing Authorization from the
European Medicines Agency (EMA3). However, it should be
noted that the efficacy of vaccines for this disease have yet to be
assessed on a large scale, and challenges in vaccine dose supply
worldwide should be overcome. Moreover, the approval by
worldwide regulatory agencies of effective and un-restricted
treatments for patients already suffering from the disease is
urgently needed.
SARS-CoV-2 is a positive-sense single-stranded RNA virus
belonging to the β-genus of the Coronaviridae family (Wan
et al., 2020) and is closely related to coronaviruses responsible
for the SARS and MERS outbreaks that spread in 2003 and 2012,
respectively (Zhu et al., 2020). Although outbreaks deriving from
coronavirus infections appear to be recurrent (Zhu et al., 2020), no
specific antiviral drugs are currently available to treat these
diseases. Therefore, major efforts are currently focused on
developing vaccines, as well as effective drugs to treat infected
patients (Clinicaltrials.gov4). Indeed, the first COVID-19 vaccine
has been approved after the submission of the present study. In the
meanwhile, many biological targets are now under investigation to
develop SARS-CoV-2-specific antiviral compounds, the most
studied being the RNA-dependent RNA polymerase, the spike
protein, and the main protease (Morse et al., 2020). Moreover, the
number of clinical trials based on antivirals developed for other
infections or drugs meant to reduce inflammation and severe
respiratory complications are now increasing at previously
unseen rates (Clinicaltrials.gov4). Currently investigated
antivirals include favipiravir, an anti-influenza drug, which
resulted effective also against the Ebola virus (ClinicalTrials
Identifiers: NCT04303299, NCT04310228, NCT04349241), and
the RNA-dependent RNA polymerase prodrug inhibitor
remdesivir, which was shown to be effective also against MERS
and SARS (Clinicaltrials.gov)5. Indeed, remdesivir has very recently
been reported to significantly reduce the median recovery time of
COVID-19 patients and has been approved by FDA as a
therapeutic option in hospital settings (Beigel et al., 2020).
Moreover, boceprevir, which is a NS3/4A serine protease
inhibitor used in the treatment of chronic Hepatitis C, has also
very recently gained the attention of the research community for
COVID-19 treatment (Fu et al., 2020). Hydroxychloroquine was
also investigated for the treatment of COVID-19, but clinical trials
on this compound were stopped by theWorld Health Organization
in June 2020 (Who.int6). Moreover, hydroxychloroquine did not
show significant activity on COVID-19 hospitalized patients,
according to recently retrieved clinical data (RECOVERY
Collaborative Group et al., 2020b). The monoclonal antibodies
tocilizumab and sarilumab directed against the interleukin-6
receptor (IL-6R) have entered clinical trials (ClinicalTrials
Identifiers: NCT04322773, NCT04332913) for the same
purpose. Finally, the use of dexamethasone was endorsed by the
European Medicines Agency to treat hospitalized patients with
COVID-19 (RECOVERY Collaborative Group et al., 2020a).
The rapid spread of the SARS-CoV-2 pandemic and the lack of
specific antiviral drugs suggest that drug repurposing should be
the preferred way for rapidly selecting suitable candidates for
clinical testing (Senanayake, 2020). Indeed, these compounds are
well characterized and already possess optimized
pharmacokinetics and safety profiles. In this scenario,
computational approaches can provide new opportunities for
drug repurposing (March-Vila et al., 2017), allowing the
identification of valuable drug candidates to be used either
alone or in combination. These approaches take advantage of
curated databases reporting chemical, structural and activity
information on different protein targets and already known
therapeutic effects (e.g., PubChem, ChEMBL, DrugBank), or
other repositories specifically focusing on repurposing data
(e.g., ReframeDB and Drug Repurposing Hub) and COVID-19
databases (e.g., NIH7), which are currently available for already
approved or under clinical evaluation COVID-19 drugs (Corsello
et al., 2017; Gaulton et al., 2017; Janes et al., 2018; Wishart et al.,
2018; Kim et al., 2019). Moreover, considering the severe life-
threatening disease complications, polypharmacological drugs,
i.e., single drug molecules that combine antiviral activity with e.g.,
anti-inflammatory or antithrombotic activity, may be particularly
useful (Anighoro et al., 2014). To this end, in this study we
performed an extensive structure-based virtual screening
campaign and identified 22 top-candidate approved or
experimental drugs as potential inhibitors of the SARS-CoV-2
main protease (Mpro). The DrugBank database (Wishart et al.,
2018), including drug metabolites, was docked to the Mpro
enzyme and the results were post-processed with BEAR
(Rastelli et al., 2009), an in-house developed screening tool
with a well-documented ability to refine virtual screening
results (Rastelli and Pinzi, 2019). Moreover, retrospective
structure-based analyses were performed on a set of
compounds with already known SARS-CoV-2 Mpro activity, to
further validate the adopted in silico structure-based protocol.
The candidate selection process took into special consideration
the analysis of drug annotations and biological activity
information reported in the literature to attain possible
favorable polypharmacological effects arising from the original
therapeutic indication. Because of their fitting to the SARS-CoV-2
2Pfizer Inc. (2020) Pfizer and Biontech to submit emergency use authorization
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authorization [Accessed November 23, 2020].
3EMA (2020) https://www.ema.europa.eu/en/news/ema-recommends-first-covid-
19-vaccine-authorisation-eu [Accessed December 21, 2020].
4Clinicaltrials.gov (2020) COVID-19. https://clinicaltrials.gov/ct2/results?
cond!COVID-19&term!&cntry!&state!&city!&dist! [Accessed November 6,
2020].
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main protease active site, the reported drugs could be readily
repurposed to elicit an antiviral response.
MATERIALS AND METHODS
The recently reported 6LU7 crystal structure of the SARS-CoV-2
main protease (Jin et al., 2020) was first collected from the Protein
Data Bank (accessed on March 17th, 2020) and then prepared for
the in silico screening process using the Protein Preparation
Wizard (Protein Preparation Wizard, Schrödinger, LLC, New
York, NY, 2020). Defaults parameters were used during the
protein preparation. Atom types and connectivity issues were
fixed, hydrogen atoms were added, and interaction geometries
were optimized. The co-crystallized water molecules and the
peptide-like PRD_002214 inhibitor (compound N3) were
retained during the protein preparation process, while they were
removed in the following docking and post-processing phases.
Docking calculations were performed in the active site of the
prepared 6LU7 crystal structure by using Glide (Glide,
Schrödinger, LLC, New York, NY, 2020; Friesner et al., 2004)
with the Standard Precision (SP) protocol. Specifically, the
receptor grid was first generated on the coordinates of the co-
crystallized PRD_002214 ligand, with a box of (10 Å × 10 Å ×
10 Å) dimensions (default settings). Then, the docking protocol
was validated by redocking the co-crystallized ligand into its
parent crystal structure, with satisfactory results.
Approved drugs, clinical and preclinical candidates, and
metabolites were first downloaded from the DrugBank
database (www.drugbank.ca, accessed on March 17th, 2020),
and then prepared for the structure-based calculations using
the LigPrep utility (LigPrep, Schrödinger, LLC, New York, NY,
2020). Specifically, ionization states and tautomers at pH values
equal to 7 ± 2 were first generated for each ligand in the screening
database and thenminimized according to the OPLS3e force field.
Stereoisomers were also generated for the DrugBank ligands with
undefined chiralities. Subsequently, the pre-treated compounds
were screened with the validated docking protocol. Finally, the
predicted poses were visually inspected, and the first 2000 top-
scoring ligand-protein complexes were further post-processed
with the BEAR post-docking tool (Rastelli et al., 2009).
The BEAR protocol consists of three steps based on
molecular mechanics (MM) minimization and molecular
dynamics cycles, followed by more accurate binding free
energy estimation of the refined complex with the MM-
PBSA and MM-GBSA methods (Rastelli et al., 2009).
Further details on the BEAR post-processing procedure,
which was shown to considerably increase the prediction
performances in several virtual screening campaigns, are
reported by (Rastelli et al., 2009).
A final step of visual inspection of the refined complexes
and their comparison with the corresponding poses predicted
by Glide aided in the final selection of the potential candidates
for the SARS-CoV-2 main protease inhibition. Analysis of
data annotation and literature searches returned a set of top
candidates with a potentially beneficial polypharmacology
profile.
Retrospective structure-based calculations were also performed
with the previously described protocol on a set of compounds
(Supplementary Table S1) with recently reported activity data
on the SARS-CoV-2 Mpro (Dai et al., 2020; Jin et al., 2020; Ma
et al., 2020). Finally, results were visually inspected and the obtained
scores compared with those from the performed virtual screening.
RESULTS
The SARS-CoV-2 main protease (Mpro), also known as 3C-like
protease, is a relevant target for drug repurposing because it plays
a crucial role in the maturation of the viral particle (Jin et al.,
2020). Indeed, this cysteine protease presents a highly conserved
active site in several coronaviruses, such as SARS-CoV and
MERS-CoV, and plays a key role in the cleavage of precursor
polyproteins translated from viral RNA.
A computational screening workflow (Figure 1) was devised
to identify drug candidates able to bind and inhibit the SARS-
CoV-2 main protease. To this end, the complete DrugBank
database (Release Version 5.1.5, 13,227 compounds, accessed
on March 17th, 2020), including drug metabolites, was docked
to the crystal structure of the SARS-CoV-2 main protease (PDB
ID: 6LU7) (Jin et al., 2020) using Glide (Glide, Schrödinger, LLC,
New York, NY, 2020; Friesner et al., 2004), and the results were
ranked according to the Glide “Docking score” scoring function.
The 2000 top ranking compounds were post-processed with
BEAR (Rastelli et al., 2009; Rastelli and Pinzi, 2019). BEAR is an
automated procedure that combines the structural refinement of
docking poses through molecular dynamics, which accounts for
protein flexibility, with the re-ranking of ligands on the basis of
binding free-energies. Binding free energies of the refined
complexes are calculated through the molecular mechanics
generalized Born surface area (MM-GBSA) and molecular
mechanics Poisson Boltzmann surface area (MM-PBSA)
scoring functions, which implicitly account for solvation
effects (Rastelli et al., 2009). Then, the best candidates were
selected according to i) docking and post-docking scores,
which provide an estimation of the binding affinity of a ligand
to a target, ii) visual inspection of the protein-ligand complexes,
and iii) analysis of drug annotations and literature information to
repurpose known drugs, clinical candidates or experimental
compounds as Mpro inhibitors that may benefit from their
original therapeutic indications to reduce severe COVID-19
complications, while inhibiting viral particle maturation
(beneficial polypharmacology (Anighoro et al., 2014)).
Interestingly, several ligands already present in the DrugBank
database, which were very recently confirmed as inhibitors of the
SARS-CoV-2 Mpro enzyme, turned out to be among the top-
scored compounds in our virtual screening campaign (see
Supplementary Table S1), thus demonstrating that the used
protocol is able to identify active compounds within the
screened database. Moreover, to further validate the ability of
the used in silico workflow to aid in the identification of
candidates with potential SARS-CoV-2 Mpro activity,
retrospective analyses were also performed on a set of
inhibitors extracted from the literature and not included in the
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DrugBank database. In particular, ligand structures were first
collected from their reference publications (Dai et al., 2020; Jin
et al., 2020; Ma et al., 2020), built and prepared for structure-
based calculations. Then, docking calculations followed by BEAR
binding-free energy estimations were performed, as detailed in
the “Materials and Methods” section. Notably, the majority of
retrospectively investigated compounds with known activity data
(i.e., 16 out of 23; ∼70% of the validation dataset) provided
comparable docking scores to those of the 2,000 top ranking
compounds (Glide “Docking scores” lower than −7.18 Kcal/mol),
therefore, these compounds would have been selected for further
investigations in our workflow. Moreover, it should be noted that
the seven known SARS-CoV-2 Mpro inhibitors discarded at this
stage by our workflow present a chemical structure significantly
different to that of the crystallographic ligand, and it is widely
acknowledged that docking results can be strongly affected by the
selected receptor conformation (Broccatelli and Brown, 2014).
Finally, results of the BEAR calculations on the retrospectively
investigated compounds further strengthen the soundness of the
implemented workflow. Indeed, the most active compounds in
the validation dataset provided BEAR GB and PB scores
comparable to those of the best-ranking ligands in the
screened database (Supplementary Table S1).
The most promising compounds resulting from the virtual
screening are reported inTable 1, along with their DrugBank IDs,
the predicted docking and binding free energy scores, the rank
position in the screening outcome, the therapeutic targets and
original indications, and the PDB IDs of the crystal structure of
each drug in complex with its original target, when available.
The 2D chemical structures of the selected candidates are
reported in Supplementary Material S1. A detailed discussion
of the selected drug candidates divided into candidates for drug
repurposing, candidates for drug repurposing with beneficial
polypharmacology, and candidates for drug repurposing based
on active drug metabolites, is reported in the following
paragraphs.
Candidates for Drug Repurposing
The drugs herein reported (either approved or investigational)
are excellent examples of potential candidates for repurposing as
SARS-CoV-2 Mpro inhibitors. Indeed, all compounds are well
accommodated in the SARS-CoV-2 Mpro catalytic site. Moreover,
as evidence of the reliability of our results, several of the proposed
candidates are viral protease inhibitors, which in some cases are
already under study as COVID-19 therapeutic agents (see below).
The hydroxymethyl ketones EXPT02467 (cruz-2, DB02128)
and EXPT02989 (cruz-1, DB01871) are two reversible inhibitors
of cruzipain, a cysteine-type endopeptidase of Trypanosoma cruzi
(Cazzulo et al., 1990). The structures of their complexes with the
cruzipain target are available under the PDB IDs 1ME3 and
1ME4, respectively. Another interesting cruzipain inhibitor that
emerged from our screening is WRR-204 (EXPT03235,
DB04502), which is an irreversible inhibitor (PDB ID: 1EWO).
To the best of our knowledge, these compounds have never been
investigated for drug repurposing, including on COVID-19
related therapeutic targets.
MMI-175 (DB02378) is an experimental drug that inhibits
β-secretase (BACE-1) (Ghosh et al., 2005), one of the two
aspartic proteases responsible for the generation of amyloid-β
peptides in neurons. As such, drugs blocking this enzyme may
aid in slowing down Alzheimer’s disease progression. According to
the predicted docking pose (Figure 2, panel (A)) and binding
affinities, this compound is expected to efficiently bind to the
SARS-CoV-2 Mpro enzyme. The ability of this compound to
cross the blood-brain barrier would be of great interest for
COVID-19 treatment, as previous studies have reported the
FIGURE 1 | Computational workflow of the repurposing screening for the identification of SARS-CoV-2 main protease inhibitors.
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TABLE 1 | Drug candidates selected from the computational repurposing campaign.













Candidates for drug repurposing




DB02128 Cruz-2; EXPT02467 −9.4 −62.7 −40.4 82 187 65 1ME3 Cruzipain (P25779) Chagas disease
(experimental)
DB02378 MMI-175; EXPT02196 −12.0 −82.7 −62.5 3 20 1 1XS7 β-Secretase 1 (P56817) Alzheimer’s disease
(experimental)
DB03063 EH58; EXPT01332 −12.2 −65.4 −46.4 2 129 21 1LF3 Plasmepsin-2 (P46925) Malaria (experimental)
DB03648 EXPT00713 −11.2 −73.2 −40.0 8 48 72 1RL4 Formylmethionine
deformylase (Q8I372)
Malaria (experimental)
DB04353 QF34; EXPT02729 −10.0 −60.9 −39.7 35 229 77 1IZH;
1IZI
HIV-1 protease (O90777) HIV-1 infection
(experimental)
DB04378 RS370; EXPT02746 −9.0 −50.6 −28.9 121 612 511 1LF2 Plasmepsin-2 (P46925) Malaria (experimental)
DB04502 WRR-204;
EXPT03235
−9.0 −63.8 −33.1 118 165 257 1EWO Cruzipain (P25779) Chagas disease
(experimental)
DB04595 N3; PRD_002214 −9.9 −58.4 −35.8 42 292 151 6LU7 SARS-CoV-2 main protease SARS-CoV-2 infection
(experimental)
DB04692 I2 −10.2 −69.8 −49.0 25 74 11 2D2D 3C-like proteinase (P0C6X7) SARS-CoV infection
(experimental)
DB04710 N1 −9.1 −64.0 −34.3 117 159 195 1WOF;
2AMP
3C-like proteinase (P0C6X7) SARS-CoV infection
(experimental)
DB08732 WRR-183 −9.5 −52.1 −29.9 65 526 441 2OP9 SARS-CoV replicase
polyprotein 1a (P0C6U8);
SARS-CoV replicase
polyprotein 1 ab (P0C6X7)
SARS-CoV infection
(experimental)
DB11938 Difelikefalin −11.1 −77.9 −34.0 9 32 217 κ-Opioid receptor (P41145) Acute pain and post-
operative pain treatment
(investigational)
Candidates for drug repurposing with beneficial polypharmacology
DB03395 Enalkiren −9.7 −67.9 −45.3 56 89 27 Renin (P00797) Agent acting on the
renin-angiotensin
systemb
DB04653 Calpain inhibitor IV;
ZLLYCH2F


























Candidates for drug repurposing based on active drug metabolites
DBMET00084
Ritonavir M7a −7.6 −62.5 −49.7 935 194 9 HIV-1 protease (O90777) HIV-1 infectiona
DBMET01548
Saquinavir M10a −10.5 −66.0 −38.9 20 119 90 HIV-1 protease (O90777) HIV-1 infectiona
DBMET01549
Saquinavir M2 −10.5 −67.7 −40.2 19 92 68 HIV-1 protease (O90777) HIV-1 infectiona
DBMET01550
Saquinavir M2 −10.5 −62.6 −31.8 18 192 320 HIV-1 protease (O90777) HIV-1 infectiona
Compound DB04595, which is a SARS-CoV-2 Mpro inhibitor, emerged in a previous computational screening and is shown in italics.
For metabolites, therapeutic targets and indications of their parent drugs are shown.
Glide (“Docking Score”), BEAR GB (binding free-energy estimation through the MM-GBSAmethod) and BEAR PB (binding free-energy estimation through the MM-PBSAmethod) values
were used to estimate the ligand-protein binding affinity (values are reported in kcal/mol).
Bibliographic references of the crystal structures are reported in Supplementary Table S2.
aData retrieved from: ChEMBL, accessed on April 20th, 2020.
bData retrieved from: https://www.drugs.com, accessed on April 20th, 2020.
cData retrieved from: KEGG, accessed on April 23rd, 2020.
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presence of coronavirus particles in the CNS and their potential
association with neurologic manifestations in patients (Baig et al.,
2020). Also in this case, the compound emerged for the first time as a
putative candidate for drug repurposing, according to the available
literature data.
EH58 (EXPT01332, DB03063) is a potent inhibitor of plasmepsin
2, an aspartic protease in the food vacuole of Plasmodium falciparum
(PDB ID: 1LF3), and exhibits antimalarial activity (Ki ! 100 nM)
(Asojo et al., 2003). Another plasmepsin 2 inhibitor worthy of
consideration, even if predicted scores are lower than those of
EH58, is RS370 (DrugBank ID: DB04378, PDB ID: 1LF2), with a
reported Ki of 30 nM on its original target (Asojo et al., 2002).
EXPT00713 (DB03648) is a P. falciparum formylmethionine
deformylase inhibitor with a reported IC50 of 130 nM (Robien
et al., 2004). Interestingly, several antimalarial drugs are under
the spotlight of COVID-19 investigations (Gendrot et al., 2020).
The possibility of repurposing these compounds for the COVID-19
treatment would provide great benefits for cases of malaria and
SARS-CoV-2 co-infections. This is especially important in those
countries where malaria is endemic, considering that COVID-19
early symptoms (e.g., fatigue and fever) might result in misleading
clinical diagnoses (Di Gennaro et al., 2020).
QF34 (EXPT02729, DB04353) is a pseudopeptide inhibitor of
several variants of HIV-1 and HIV-2 proteases (Weber et al.,
2002), including those of some highly resistant mutants. The
compound was also crystallized with the HIV-1 protease (PDB
IDs: 1IZH, 1IZI). Interestingly, the identification of ligands with
already optimized safety profiles and reported HIV activity might
FIGURE 2 |Binding mode of MMI-175 (A), WRR-183 (B), enalkiren (C) and calpain inhibitor IV (D) to the 6LU7 crystal structure. The SARS-CoV-2Mpro binding site
residues and the potential repurposed compounds are represented in deepteal and raspberry sticks, respectively. The image was created with PyMol (The PyMOL
Molecular Graphics System, Version 2.1.1, Schrödinger, LLC).
Frontiers in Pharmacology | www.frontiersin.org February 2021 | Volume 12 | Article 6369896
Pinzi et al. Polypharmacology and Repurposing Against SARS-CoV-2
be particularly effective for HIV/SARS-CoV-2 co-infected
patients, which, unfortunately, seem to have poorer prognoses
(Bhaskaran et al., 2020).
Compounds I2 (DB04692), N1 (DB04710) andN3 (PRD_002214,
DB04595), three experimental inhibitors of the SARS-CoV Mpro
reported in 2005, may also be valuable candidate inhibitors of the
SARS-CoV-2 Mpro. Compounds I2, N1, and N3 were co-crystallized
in complex with the SARS-CoV Mpro (PDB IDs: 2D2D, 1WOF, and
2AMQ, respectively). Notably, compound N3 has been very recently
confirmed to bind and inhibit the SARS-CoV-2 Mpro, and the crystal
structure of its complex was the starting point of our virtual screening
(PDB ID: 6LU7) (Jin et al., 2020).
Compound WRR-183 (DB08732) is an α,β-epoxyketone that
irreversibly inhibits the SARS-CoV Mpro (PDB ID 2OP9) (Goetz
et al., 2007). According to our docking results, this compound was
predicted to bind to the SARS-CoV-2Mpro tightly and with a similar
binding mode, where the epoxide is in close proximity to the Cys
residue (Figure 2, panel (B)). Moreover, WRR-183 and especially its
C-2 (R) epoxide isomer WRR-182 are highly active against the
SARS-CoV spike-mediated entry (Zhou et al., 2011). Therefore, they
show the potential to block SARS-CoV and, hopefully, SARS-CoV-2
at two different steps of the replication cycle, i.e., viral entry and
particle assembly (Zhou et al., 2011).
Difelikefalin (formerly known as CR-845, DB11938) is a
highly selective agonist of the κ-opioid receptor (Keppel
Hesselink, 2017). This analgesic opioid peptide acts
peripherally and is under investigation for the treatment of
acute and post-operative pain and, more recently, chronic
pruritus (Keppel Hesselink, 2017). Difelikefalin is currently in
two Phase II clinical trials for the treatment of pruritus in atopic
dermatitis and biliary cholangitis (Clinical Trials Identifiers:
NCT04018027 and NCT03995212). The peripheral analgesic
activity of the compound, together with its potential SARS-
CoV-2 Mpro activity, may prove beneficial to COVID-19
patients experiencing peripheral neurologic symptoms and pain.
Candidates for Drug Repurposing With
Beneficial Polypharmacology
Polypharmacological ligands are extremely interesting in drug
repurposing, because they offer the potential for higher efficacy
and a combination of synergistic effects (Anighoro et al., 2014).
Therefore, for each top-ranking compound, we carefully
investigated whether a possible beneficial polypharmacological
effect may arise owing to the reported biological activities and
original therapeutic indications.
Enalkiren (DB03395) belongs to the class of direct renin
inhibitors. By mimicking the transition state of angiotensin,
enalkiren is able to block the first step of the renin-angiotensin
system (Glassman et al., 1990). Interestingly, hypertension is among
the most common comorbidities in hospitalized COVID-19
patients, and is often treated with angiotensin II receptor blockers
or angiotensin-converting enzyme (ACE) inhibitors (Ran et al.,
2020). Unfortunately, it has been recently reported that SARS-
CoV-2 binds to the widespread angiotensin-converting enzyme 2
receptor to enter target cells (Bavishi et al., 2020) and that levels of
serum angiotensin II are considerably increased in COVID-19
patients (Liu et al., 2020b). Moreover, the use of drugs lowering
blood pressure through such mechanisms might lead to
overexpression of ACE2, thus potentially increasing the
susceptibility to SARS-CoV-2 in patients (Fang et al., 2020).
Based on these premises, the possibility of enalkiren to modulate
the renin-angiotensin system without altering patient susceptibility
to the virus, together with inhibition of the SARS-CoV-2 Mpro, may
exhibit beneficial effects for COVID-19 treatment. According to our
docking results, enalkiren is well accommodated within the SARS-
CoV-2Mpro binding site (Figure 2, panel (C)). Interestingly, another
very recent computational study based on a different workflow also
identified enalkiren as a potential candidate to target the SARS-CoV-
2 Mpro, further supporting its selection as a promising candidate for
COVID-19 treatment (Liu et al., 2020a).
The calpain inhibitor IV (ZLLYCH2F, DB04653) is a covalent
inhibitor of the calpain-1 cysteine protease (PDB ID: 1ZCM) that
regulates the activity of proteins involved in processes influencing
neuronal plasticity, cognition and neurodegeneration (Vosler et al.,
2008) and is a potential target for intervention in inflammatory
diseases (Cuzzocrea et al., 2000). In our docked structure (Figure 2,
panel (D)), the reactive methylene group of the compound is in close
proximity to the Cys residue of the SARS-CoV-2 Mpro active site.
This result indicates that a covalent bond can potentially be formed
that would provide specificity and higher affinity over other
proteases. Interestingly, in 2004, calpain inhibitor IV was shown
to be an active agent against SARS-CoV (Barnard et al., 2004) and its
potential use against SARS-CoV-2 has also very recently been
proposed in other repurposing studies (Abhithaj et al., 2020).
Moreover, other calpain inhibitors have recently been tested for
inhibition of the SARS-CoV-2 Mpro and among them the calpain
inhibitor XII was shown to be the most active with an IC50 of
0.45 μM (Ma et al., 2020). Importantly, calpain inhibitor IV is
reported to also act as an inhibitor of cathepsin L (Angliker
et al., 1992), which is a necessary factor for the SARS-CoV-2
entry into host cells (Ou et al., 2020). Based on these premises,
calpain inhibitor IV represents a valuable multi-target candidate for
further clinical investigation to treat COVID-19.
Ethylsulfonamide-D-Trp-Gln-p-aminobenzamidine (DB04758)
was designed to potently inhibit factor VIIa (FVIIa), which forms
a complex with tissue factor (TF) to initiate the extrinsic coagulation
cascade (Kadono et al., 2005). Compared with other anti-thrombotic
agents, the specific targeting of the extrinsic coagulation provides a
decreased risk of bleeding. SARS-CoV-2 infection often has dramatic
consequences for the circulatory system (Tang et al., 2020b), with
preliminary reports including thrombocytopenia, elevated d-dimer
levels, prolonged prothrombin time, and disseminated intravascular
coagulation (Han et al., 2020). Interestingly, research findings
suggest that inhibition of TF-FVIIa complex may reduce the
cytokine storm responsible for the increased coagulation and
multi-organ failure, and thus the mortality rate in COVID-19
patients (Geisbert et al., 2003; Eslamifar et al., 2020). Our in silico
findings suggested thatDB04758 could also bindwith high affinity to
the SARS-CoV-2Mpro. Therefore, this molecule might exhibit a dual
activity against two crucial aspects of the SARS-CoV-2 infection.
Z-LY-CMK (DB07571) is a covalent inhibitor of the ATP-
dependent Clp protease proteolytic subunit (ClpP), an enzyme
that has recently gained attention as a promising drug target for
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antibiotic development (Bhandari et al., 2018). If confirmed, the
potential of this compound to act as both an antimicrobial agent
and a SARS-CoV-2 inhibitor would be particularly useful to
treat secondary bacterial infections, potentially affecting
COVID-19 patients. Moreover, a structurally similar
compound (Z LVG CHN2 in the original paper), previously
shown to inhibit the herpes simplex virus cysteine protease
(Björck et al., 1990), has recently been tested on Vero E6 cells
infected with SARS-CoV-2. Its antiviral activity (EC50 !
0.19 µM) was suggested to be due to the inhibition of the
SARS-CoV-2 Mpro (Riva et al., 2020).
The thrombin inhibitor BM51.1011 (DB07934) is another
candidate with a promising multi-target activity profile. Indeed,
this compound has been originally studied as a lowmolecular weight
inhibitor of thrombin, a class of therapeutics with anticoagulant
effects (Engh et al., 1996). The structure of BM51.1011 in complex
with the original target (thrombin) is reported in PDB ID: 1UVS.
Notably, thrombotic complications and, in particular,
coagulopathies appear to be an important issue in patients
affected by COVID-19 (Han et al., 2020). Moreover, reduced
levels of antithrombin, a protein involved in the regulation of the
coagulation cascade, have been reported in COVID-19 patients
(Arachchillage et al., 2020). Interestingly, according to recent
findings, treatment with Argatroban, a direct thrombin inhibitor
with anticoagulant effects independent from antithrombin, seems to
provide significant therapeutic effects in patients (Arachchillage
et al., 2020; Sagardia and Daniels, 2020), albeit this drug was
shown to be unable to inhibit SARS-CoV-2 replication (NIH8).
As the pandemic is spreading, the reported coagulation disorders in
COVID-19 patients as in previous SARS and MERS patients should
be carefully addressed. Based on these premises, the possibility of
BM51.1011 to exert anticoagulant and Mpro inhibitory activity, if
confirmed, would certainly provide a valuable therapeutic advantage
for COVID-19 patients.
Delparantag (formerly known as PMX-60056, DB12955) is a
top scoring candidate for all the scoring functions. This molecule
reverses the anticoagulation effects of heparin by binding to the
pentasaccharide group of unfractionated heparin (UFH) and low-
molecular-weight heparins (LMWH) (Kuziej et al., 2010).
Heparin has gained increasing attention for its ability to
prevent blood coagulation in COVID-19 patients affected by
severe pneumonia and its concomitant anti-inflammatory
effects that result in reduced IL-6 levels (Tang et al., 2020a).
However, recent studies have shown that patients with COVID-
19 can rapidly develop severe or critical vascular diseases, which
may result in venous thromboembolism and bleeding status (Xu
et al., 2020). As a close monitoring of venous thromboembolism
and bleeding risks is essential in such patients, delparantag may
be an effective tool to mitigate bleeding risks while eliciting
antiviral activity due to the potential inhibition of the SARS-
CoV-2 Mpro. To the best of our knowledge, this compound has
never been investigated in repurposing campaigns.
Candidates for Drug Repurposing Based on
Active Drug Metabolites
A unique feature of our repurposing strategy involves the inclusion of
drug metabolites among screened compounds. Although they are
typically discarded in drug repurposing studies, majormetabolites can
provide extremely interesting results. For this reason, here we describe
some of the top scoring metabolites from our screening. Remarkably,
many of these metabolites were shown to bind to the active site of the
SARS-Cov-2 Mpro with higher affinity than their parent drug.
Ritonavir and lopinavir, two HIV-1 protease inhibitors that are
administered in combination, are currently being clinically
investigated against COVID-19 (Cao et al., 2020). Unfortunately,
recent research findings showed that lopinavir or its combination
with ritonavir are not able to significantly inhibit the SARS-CoV-
2 Mpro up to a concentration of 100 µg/m (Jang et al., 2020).
However, they were shown to be slightly active on other SARS-
CoV-2 related targets, as reported in the COVID-19 open-data
portal of the National Institutes of Health (NIH9; NIH10). Based on
our in silico analyses, neither of these drugs appears to interact
favourably with the SARS-CoV-2 Mpro, although the N-desmethyl
metabolite M7 of ritonavir (DBMET00084) was demonstrated to
better interact with the protein owing to its free urea group that
establishes favourable hydrogen bonds with the SARS-CoV-2 Mpro.
The saquinavir decahydroisoquinoline metabolites M2
(DBMET01550 and DBMET01549) and t-butyl hydroxyl M10
(DBMET01548) were predicted to strongly bind to the SARS-
CoV-2 Mpro active site according to the docking scores.
Interestingly, while saquinavir metabolites are inactive against the
HIV-1 protease (Noble and Faulds, 1996), they appear to bind to the
SARS-CoV-2 Mpro binding site with a more favourable predicted
binding energy than saquinavir. This finding may be relevant for the
pharmacokinetics and dosing of this antiviral for the treatment of
COVID-19. Indeed, saquinavir was shown to be inactive against the
Mpro, as recently reported in the COVID-19 open-data portal of the
National Institutes of Health (NIH11). However, it was identified as a
putative inhibitor of the spike glycoprotein (Ramírez-Salinas et al.,
2020), and lately confirmed as active (NIH11). If experimentally
confirmed, the potential activity of saquinavir metabolites on both
the spike glycoprotein and the Mpro would result in beneficial effects
on COVID-19 patients.
DISCUSSION
The goal of the present study was to perform a systematic drug
repurposing screening of compounds from the DrugBank
8National Institutes of Health (2020) COVID-19 - OpenData Portal – Argatroban.
https://opendata.ncats.nih.gov/covid19/databrowser?q!argatroban [Accessed
December 22, 2020].
9National Institutes of Health (2020) COVID-19 - OpenData Portal – Ritonavir.
https://opendata.ncats.nih.gov/covid19/databrowser?q!Ritonavir [Accessed
December 22, 2020].
10National Institutes of Health (2020) COVID-19 - OpenData Portal – Lopinavir.
https://opendata.ncats.nih.gov/covid19/databrowser?q!lopinavir [Accessed
December 22, 2020].
11National Institutes of Health (2020) COVID-19 - OpenData Portal – Saquinavir.
https://opendata.ncats.nih.gov/covid19/databrowser?q!saquinavir [Accessed
December 22, 2020].
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database for their ability to bind to the SARS-CoV-2 main
protease. The performed analyses allowed the selection of 22
drugs or experimental compounds, which, to the best of our
knowledge, can be considered “novel”, as they had not yet been
included in COVID-19 clinical trials at the time of manuscript
submission. Notably, several DrugBank compounds already
reported as active against the SARS-CoV-2 Mpro scored among
the top-ranked ligands, suggesting that the implemented protocol
is able to correctly identify active ligands. Moreover, retrospective
analyses were also performed on an additional set of known
SARS-CoV-2 Mpro inhibitors, not included in the screened
database, thus allowing to further validate the in silico
workflow. Interestingly, many of the identified candidates
could be able to combine a potential antiviral activity with
other activities, e.g., antithrombotic or anti-inflammatory
activity, due to their activity on the primary target and
therapeutic indication. Such “polypharmacological” behavior, if
confirmed, would make the identified candidate drugs extremely
attractive to be further evaluated for COVID-19 treatment.
Indeed, a single molecule would be able to concurrently exert
an antiviral activity and mitigate or abolish COVID-19
comorbidities, the severity of which often leads to patient
death. Therefore, in this study the importance of these
repurposed molecules is also discussed from a
polypharmacologic perspective. Furthermore, we identified a
number of drug metabolites that appeared to be stronger
binders of the SARS-CoV-2 Mpro than the parent drugs (e.g.,
saquinavir and ritonavir metabolites). To the best of our
knowledge, drug repurposing based on drug (major)
metabolites represents a novel approach that may offer
additional and valuable opportunities to repurpose candidate
drugs through the modulation of in vivo pharmacokinetics. In
addition, the in-depth analysis of currently available literature
data, including cell-based results on SARS-CoV-2 infected cells,
further substantiate the relevance of the potential Mpro inhibitors
selected in this work. Given the drastic need for therapeutic
options for COVID-19, our results can suggest some key drugs for
repurposing.
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